Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ziyong Xiang"'
Autor:
Jie Yi, Yongjing Lei, Shiyuan Xu, Yongyu Si, Shiyang Li, Zhongyuan Xia, Yisa Shi, Xiaoping Gu, Jianshe Yu, Guohai Xu, Erwei Gu, Yonghao Yu, Yanqing Chen, Hequn Jia, Yinglin Wang, Xiuli Wang, Xiaoqing Chai, Xiaoju Jin, Junping Chen, Meiying Xu, Junyu Xiong, Guonian Wang, Kaizhi Lu, Wenli Yu, Weifu Lei, Zaisheng Qin, Jingguo Xiang, Longyun Li, Ziyong Xiang, Shuang Pan, Lujing Zhan, Kai Qiu, Min Yao, Yuguang Huang
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0177221 (2017)
Inadvertent intraoperative hypothermia (core temperature 2 h) (OR = 2.60, 95% CI 2.09-3.24).The incidence of intraoperative hypothermia in China is high, and the rate of active warming of patients during operation is low. Hypothermia is associated wi
Externí odkaz:
https://doaj.org/article/76c65fc8a833404ea4fbf4ee6c9bd3c2
Autor:
Jie Yi, Ziyong Xiang, Xiaoming Deng, Ting Fan, Runqiao Fu, Wanming Geng, Ruihong Guo, Nong He, Chenghui Li, Lei Li, Min Li, Tianzuo Li, Ming Tian, Geng Wang, Lei Wang, Tianlong Wang, Anshi Wu, Di Wu, Xiaodong Xue, Mingjun Xu, Xiaoming Yang, Zhanmin Yang, Jianhu Yuan, Qiuhua Zhao, Guoqing Zhou, Mingzhang Zuo, Shuang Pan, Lujing Zhan, Min Yao, Yuguang Huang
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0136136 (2015)
Inadvertent intraoperative hypothermia (core temperature 2 h (OR = 3.44, 95% CI 1.90-6.22,), and intravenous un-warmed fluid (OR = 2.45, 95% CI 1.45-4.12) significantly increased the risk of hypothermia.The incidence of inadvertent intraoperative hyp
Externí odkaz:
https://doaj.org/article/f1d2b4cc9a5e4ef78330497ee93dfaf9
Autor:
Timothy Price, Jaspreet Grewal, Afaf Abed, Melissa Moore, Yu-Min Yeh, Shirish Gadgeel, Gary Richardson, Craig Underhill, Vinod Ganju, Keun-Wook Lee, Seok Jae Huh, Sang-We Kim, Chih-Hsin Yang, Yuh-Min Chen, Ziyong Xiang, Zhe Shi, Yaolin Wang, Ling Zhang, Michael Millward
Publikováno v:
Cancer Research. 82:CT504-CT504
Background: KRASG12C mutation is an oncogenic driver that occurs in approximately 15% of non-small cell lung cancer (NSCLC), 3% of colorectal cancer (CRC), and ~1% of several other solid tumors. D-1553 is a novel, potent and orally bioavailable KRASG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::349cef647ecdcd2619623e7939612add
https://doi.org/10.1158/1538-7445.am2022-ct504
https://doi.org/10.1158/1538-7445.am2022-ct504
Autor:
Hong Jian, Zhenbo Song, Yiping Zhang, Kunyan Li, Nong Yang, Melissa Moore, Pingli Wang, Yanqiu Zhao, Yi Gong, Craig Underhill, Sang-We Kim, Cheng-Ta Yang, Ziyong Xiang, Zhe Shi, Ling Zhang, Yaolin Wang, Shun Lu
Publikováno v:
Cancer Research. 82:CT505-CT505
Background: KRASG12C mutation acts as an oncogenic driver and occurs in ~15% of NSCLC. D-1553 is a novel and potent small molecule inhibitor of KRASG12C. Here we present the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of D-15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::097b7f2ff176bf4bd4acb814467db8b2
https://doi.org/10.1158/1538-7445.am2022-ct505
https://doi.org/10.1158/1538-7445.am2022-ct505
Autor:
Yi-Long Wu, Minghui Sun, Xue-Ning Yang, Yue Li, Hua-Jun Chen, Qing Zhou, Jin-Ji Yang, Ziyong Xiang
Publikováno v:
Journal of Clinical Oncology. 38:e21702-e21702
e21702 Background: Aberrant activation of the MET pathway is associated poor prognosis and poor response to standard therapies in cancer patients. Glumetinib (SCC224) is an oral potent and highly selective MET inhibitor. This is an open label, dose-e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf7524cb8587bad4983f2b969b9275f5
https://doi.org/10.1200/jco.2020.38.15_suppl.e21702
https://doi.org/10.1200/jco.2020.38.15_suppl.e21702
Autor:
Guohai Xu, Jianshe Yu, Yinglin Wang, Meiying Xu, Min Yao, Yuguang Huang, Zaisheng Qin, Shuang Pan, Yongyu Si, Erwei Gu, Xiu-Li Wang, Yanqing Chen, Guonian Wang, Yisa Shi, Xiaoju Jin, Junping Chen, Li Ll, Hequn Jia, Kai Qiu, Xiaoping Gu, Ziyong Xiang, Shiyang Li, Wenli Yu, Junyu Xiong, Yonghao Yu, Jingguo Xiang, Yongjing Lei, Xiaoqing Chai, Zhongyuan Xia, Kaizhi Lu, Weifu Lei, Shiyuan Xu, Jie Yi, Lujing Zhan
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0177221 (2017)
PLoS ONE
PLoS ONE
Background/Objective Inadvertent intraoperative hypothermia (core temperature 2 h) (OR = 2.60, 95% CI 2.09–3.24). Conclusions The incidence of intraoperative hypothermia in China is high, and the rate of active warming of patients during operation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d5e18910059fa896419bbe7d4a6c1e
http://europepmc.org/articles/PMC5464536?pdf=render
http://europepmc.org/articles/PMC5464536?pdf=render
Autor:
Chenghui Li, Ming Tian, Xiao-Ming Yang, Jie Yi, Xiaodong Xue, Tianlong Wang, Wanming Geng, Geng Wang, Tianzuo Li, Lei Li, Shuang Pan, Qiuhua Zhao, Mingjun Xu, Guoqing Zhou, Anshi Wu, Min Li, Ziyong Xiang, Di Wu, Yuguang Huang, Nong He, Jianhu Yuan, Runqiao Fu, Xiaoming Deng, Min Yao, Zhanmin Yang, Lei Wang, Mingzhang Zuo, Ting Fan, Lujing Zhan, Ruihong Guo
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0136136 (2015)
PLoS ONE
PLoS ONE
Background/Objective Inadvertent intraoperative hypothermia (core temperature 2 h (OR = 3.44, 95% CI 1.90–6.22,), and intravenous un-warmed fluid (OR = 2.45, 95% CI 1.45–4.12) significantly increased the risk of hypothermia. Conclusions The incid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50e6bcfa1a3739fa4195c19554dabbd8
https://doi.org/10.1371/journal.pone.0136136
https://doi.org/10.1371/journal.pone.0136136